Review of 2008: Next-gen DESs bid to upset the status quo
This article was originally published in Clinica
Executive Summary
In 2008, two new drug-eluting stents (DESs) were launched onto the US market, making a total of four different products available to US-based cardiologists. The launches of these devices – Medtronic's Endeavor in February and, in July, Abbott's Xience V – came as confirmation, if it were needed, of the cardinal significance of DES technology. Up-and-coming firms, unable to challenge standard DESs, are aiming to displace these entrenched products by making them technologically obsolete.
You may also be interested in...
Normality Reasserts Itself For Biotech IPOs
The highs of the COVID-19 era, and the lows that supplanted it, are beginning to fade.
MRM Health Pulls A Pouchitis Hit Out Of The Bag
The mid-stage success is encouraging, but taking on Takeda won’t be easy.
Novartis Draws Out Its APPLAUSE
Another data drop from Fabhalta’s IgAN trial looks encouraging, despite a missing abstract.